Benzinga | Sep 9, 2020 07:32AM EDT

Moleculin Announces Successful Completion Of Pre-IND Meeting With FDA

HOUSTON, Sept. 9, 2020 /PRNewswire/ --Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for Annamycin, including the clinical study design and dosing strategy for the initial phase 1b/2 protocol for soft tissue sarcomas with lung metastases.